Back to Search
Start Over
Near infrared photoimmunotherapy for cancers: A translational perspective.
- Source :
-
EBioMedicine [EBioMedicine] 2021 Aug; Vol. 70, pp. 103501. Date of Electronic Publication: 2021 Jul 28. - Publication Year :
- 2021
-
Abstract
- Near-infrared photoimmunotherapy (NIR-PIT) is a newly-developed, highly-selective cancer treatment, which utilizes a monoclonal antibody conjugated to a photoabsorbing dye, IRDye700DX (IR700). The antibody conjugate is injected into the patient and accumulates in the tumour. Within 24 h of injection the tumour is exposed to NIR light which activates the conjugate and causes rapid, selective cancer cell death. A global phase III clinical trial of NIR-PIT in recurrent head and neck squamous cell cancer (HNSCC) patients is currently underway. Conditional clinical approval for NIR-PIT in recurrent HNSCC has been granted in Japan as of September 2020. Not only does NIR-PIT induce highly selective and immediate cancer cell killing, but it also stimulates highly active anti-tumour immunity. While monotherapy with NIR-PIT has proven effective it is likely that combinations with immune-checkpoint inhibitors or additional NIR-PIT targeting immune suppressive cells in the tumour microenvironment will further improve results. In this review, we discuss the translational aspects of NIR-PIT especially in HNSCC, and potential future applications.<br />Competing Interests: Declaration of Competing Interest The authors declare no conflicts of interests.<br /> (Published by Elsevier B.V.)
Details
- Language :
- English
- ISSN :
- 2352-3964
- Volume :
- 70
- Database :
- MEDLINE
- Journal :
- EBioMedicine
- Publication Type :
- Academic Journal
- Accession number :
- 34332294
- Full Text :
- https://doi.org/10.1016/j.ebiom.2021.103501